Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Xijing Hospital
National Cancer Institute (NCI)
Damanhour University
Henan Cancer Hospital
University of Colorado, Denver
University of Nebraska
Seagen Inc.
MedSIR
Centre Oscar Lambret
Centre Oscar Lambret
SOLTI Breast Cancer Research Group
Dana-Farber Cancer Institute
Mayo Clinic
ETOP IBCSG Partners Foundation
City of Hope Medical Center
Dana-Farber Cancer Institute
University of Wisconsin, Madison
Stanford University
Cedars-Sinai Medical Center
Dana-Farber Cancer Institute
Assiut University
Sermonix Pharmaceuticals Inc.
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Big Ten Cancer Research Consortium
Zetagen Therapeutics, Inc
Novartis
University of Wisconsin, Madison
University of Utah
Carrick Therapeutics Limited
Damanhour University
University of California, San Francisco
SCRI Development Innovations, LLC
Ohio State University Comprehensive Cancer Center
Mayo Clinic
MedSIR
Memorial Sloan Kettering Cancer Center
Institut Curie
Bayer
M.D. Anderson Cancer Center
Novartis
Novartis
Pfizer
National Cancer Institute (NCI)
Lund University Hospital
Pfizer
Baylor College of Medicine
Arvinas Inc.
Tanta University